ライフサイエンスコーパス: advanced cancer

1 pear to suffice for a cell to evolve into an advanced cancer.

2 ntial or spiritual distress in patients with advanced cancer.

3 lized immunotherapies to treat patients with advanced cancer.

4 ressive management of pain for patients with advanced cancer.

5 RON kinase in the prevention or treatment of advanced cancer.

6 tentially curative therapy for patients with advanced cancer.

7 secondary supportive care for patients with advanced cancer.

8 d phase I/Ib clinical trial in patients with advanced cancer.

9 onizes human OX40 signaling in patients with advanced cancer.

10 and treatment adherence in young adults with advanced cancer.

11 tool on CPR preferences among patients with advanced cancer.

12 tment adherence in young adult patients with advanced cancer.

13 ality of life, and survival in patients with advanced cancer.

14 nd-of-life decision making for patients with advanced cancer.

15 is the most common symptom in patients with advanced cancer.

16 Cancer-related-fatigue (CRF) is common in advanced cancer.

17 ing CRF and quality of life in patients with advanced cancer.

18 from a variety of chronic diseases including advanced cancer.

19 class of molecular agents designed to treat advanced cancer.

20 lieving refractory symptoms in patients with advanced cancer.

21 odifiable fall risk factors in patients with advanced cancer.

22 hocytes is a promising approach for treating advanced cancer.

23 reduced the rate at which women present with advanced cancer.

24 in patients with delirium in the setting of advanced cancer.

25 ides a hopeful new therapy for patients with advanced cancer.

26 ffering and quality of life in patients with advanced cancer.

27 ime a person is diagnosed with metastatic or advanced cancer.

28 n acceptable safety profile in patients with advanced cancer.

29 ual well-being and meaning for patients with advanced cancer.

30 d nilotinib with paclitaxel in patients with advanced cancer.

31 n with and decision making for patients with advanced cancer.

32 e transthoracic group had significantly more advanced cancer.

33 ociated with a reduction in the incidence of advanced cancer.

34 vaccines for the treatment of patients with advanced cancer.

35 s likely to be ineffective by itself against advanced cancer.

36 t of disease that is unlikely to progress to advanced cancer.

37 therapies have shown value in the setting of advanced cancer.

38 ctual EOL care received in 325 patients with advanced cancer.

39 nous doses of rhApo2L/TRAIL in patients with advanced cancer.

40 ng these decisions on behalf of a child with advanced cancer.

41 ith communication about being diagnosed with advanced cancer.

42 entions to improve the care of patients with advanced cancer.

43 effects on pain and mood among patients with advanced cancer.

44 d therapy to other families of children with advanced cancer.

45 al chemotherapy to families of children with advanced cancer.

46 liver the standard of care for patients with advanced cancer.

47 provide hope for patients with localized and advanced cancer.

48 vailable treatment options for patients with advanced cancer.

49 ity of life (QOL) and mood for patients with advanced cancer.

50 nt of resistance to therapy is inevitable in advanced cancer.

51 lated health care use among individuals with advanced cancer.

52 temic inflammatory response in patients with advanced cancer.

53 py may be relevant in fibrotic disorders and advanced cancer.

54 ative therapeutic approach for patients with advanced cancer.

55 he clinical benefit of ICIs in patients with advanced cancer.

56 anscriptomic subset across distinct types of advanced cancer.

57 elationships when one of their relatives has advanced cancer.

58 arameters independent of PS in patients with advanced cancer.

59 sion medicine trial focused on patients with advanced cancer.

60 y of life (QOL) and mood among patients with advanced cancer.

61 thnicity and rates of IPCC for patients with advanced cancer.

62 e care in the hospital for all patients with advanced cancer.

63 less optimistic message) with a patient with advanced cancer.

64 ials to assess its efficacy for treatment of advanced cancers.

65 orbidity and mortality of many patients with advanced cancers.

66 f TILs and antigen receptor gene therapy for advanced cancers.

67 ic alterations from low risk to high risk to advanced cancers.

68 associated with acquired drug resistance in advanced cancers.

69 blockade to enhance TCR gene therapy against advanced cancers.

70 s are a promising approach for patients with advanced cancers.

71 of class I PI3K inhibition in patients with advanced cancers.

72 eceived regulatory approval for treatment in advanced cancers.

73 increased expression in tumor cell nuclei of advanced cancers.

74 am of body weight) to patients with selected advanced cancers.

75 odalities for the treatment of patients with advanced cancers.

76 and activation of oncogenes is essential in advanced cancers.

77 clinical development of Hsp90 inhibitors in advanced cancers.

78 Prolonged SD was seen in a variety of advanced cancers.

79 being evaluated extensively in patients with advanced cancers.

80 at may provide novel therapeutic targets for advanced cancers.

81 pharmacodynamics of imexon in patients with advanced cancers.

82 for the treatment of only a small number of advanced cancers.

83 , suggesting that let-7 is a marker for less advanced cancers.

84 Cs, they were clonal and highly prevalent in advanced cancers.

85 al implications for therapeutic targeting of advanced cancers.

86 a successful treatment strategy for several advanced cancers.

87 GFbeta appears to promote the progression of advanced cancers.

88 losion of novel targeted immunotherapies for advanced cancers.

89 e inactivation becomes more frequent in more advanced cancers.

90 ineoplastic drug used in the clinic to treat advanced cancers.

91 ed for a normal human cell to progress to an advanced cancer?

92 tase and tensin homolog (mutated in multiple advanced cancers 1) (PTEN) is recognized as a major even

93 Erlotinib induced mutated in multiple advanced cancers 1/phosphatase and tensin homologue (MMA

94 tively characterized cohort of patients with advanced cancer, 642 of 1,168 (55%) with KRAS mutations

95 preferences of children and adolescents with advanced cancer about their end-of-life care and the fac

96 Advanced cancers acquire resistance to chemotherapy, and

97 es and in circulating ECs from patients with advanced cancers, ALK1 blockade may represent an effecti

98 The lower rates of advanced cancer among Asian and Native American women pe

99 er Center, Texas, enrolling 93 patients with advanced cancer and agitated delirium despite scheduled

100 Radiation therapy patients with advanced cancer and an estimated 5-year survival rate of

101 que cohort of more than 10,000 patients with advanced cancer and available pathological and clinical

102 eletal-related events (SRE) in patients with advanced cancer and bone metastases (excluding breast an

103 er improves quality of life in patients with advanced cancer and does not seem to shorten survival; t

104 s the existing literature on polypharmacy in advanced cancer and end-of-life settings by reviewing ev

105 Concordance between parents of children with advanced cancer and health care providers has not been d

106 uring chemotherapy, even among patients with advanced cancer and high symptom burdens.

107 human iNKT cells were limited to therapy of advanced cancer and led to only modest activation of inn

108 ppaB signaling appears to be correlated with advanced cancer and promotes tumor metastasis by influen

109 ll function is not permanently suppressed in advanced cancer and successful chemotherapy is associate

110 linical course of skeletal muscle wasting in advanced cancer and the window of possible muscle anabol

111 The sample comprises 236 patients with advanced cancer and their 38 oncologists who participate

112 rvention was effective to help patients with advanced cancer and their caregivers identify and bring

113 , longitudinal cohort study of patients with advanced cancer and their informal caregivers (n = 332 d

114 ing syndrome that affects most patients with advanced cancers and causes severe body weight loss, wit

115 d clinical evaluation in adult patients with advanced cancers and has the potential to treat tumors r

116 (MMP-2) expression is often up-regulated in advanced cancers and known to play an important role in

117 d promising results in patients with various advanced cancers and suggested that enzastaurin can be s

118 s at the initial visit, for newly identified advanced cancer, and at chemotherapy visits; assess for

119 vention involving oncologists, patients with advanced cancer, and caregivers would promote patient-ce

120 promise in phase I and II trials in various advanced cancers, and is being investigated in multiple

121 einvasive lesions, found in only a subset of advanced cancers, and showed no evidence of activation.

122 py-related hospitalizations in patients with advanced cancer are common, distressing, and costly.

123 Patients with advanced cancer are equally, if not more, concerned abou

124 Individuals with advanced cancer are immune suppressed due to myeloid-der

125 White patients with advanced cancer are more likely than black patients with

126 to overcome drug resistance in patients with advanced cancer are needed.

127 These findings may explain why more advanced cancers are more likely to resist current thera

128 he rates at which point mutations develop in advanced cancers are similar to those of normal cells.

129 ists as therapeutic agents in the setting of advanced cancers, as well as the mechanisms through whic

130 tober 2010 and March 2013, 207 patients with advanced cancer at a National Cancer Institute cancer ce

131 Advanced cancer at diagnosis, > 90 days sickness absence

132 the analysis was restricted to patients with advanced cancer at diagnosis.

133 st of criteria for referral of patients with advanced cancer at secondary or tertiary care hospitals

134 ceptor blockade has changed the treatment of advanced cancers, at times inducing prolonged remission.

135 has been proposed as a therapeutic target in advanced cancers based on increased expression in primar

136 s for a large benign tumor to evolve into an advanced cancer but <2 years for cells within that cance

137 disturbances are prevalent in patients with advanced cancer, but 24-hour polysomnography (PSG) exami

138 ing lymphocytes (TIL) is a common feature of advanced cancer, but its biological basis has remained o

139 oint blockade is revolutionizing therapy for advanced cancer, but many patients do not respond to tre

140 to PI3K/AKT/mTOR inhibitors in patients with advanced cancers, but the relevance of mutation subtype

141 These results explain how advanced cancer cells usurp components of the host innat

142 therapeutic interventions for metastatic or advanced cancer; complexities of prevention trial design

143 ectations and end-of-life care wishes in the advanced cancer context, the communication support progr

144 A sizeable proportion of patients with advanced cancer continue to undergo cancer screening tes

145 015, focused entirely on the question of why advanced cancer cure is so uncommon despite the extraord

146 In advanced cancer, current conventional therapies or immun

147 Patients with advanced cancer diagnoses eligible for studies of target

148 ta were collected for adult patients with an advanced cancer diagnosis admitted to five US hospitals

149 Patients with an advanced cancer diagnosis and failure of first-line chem

150 Among women following advanced cancer diagnosis compared with controls, at lea

151 Among men following advanced cancer diagnosis compared with controls, PSA te

152 eptomeningeal metastases, within 3 months of advanced cancer diagnosis for patients with median survi

153 hospital stay for patients admitted with an advanced cancer diagnosis.

154 In MNU-induced advanced cancers, DNA methylation at the Tff1 promoter w

155 ss in 104 children age 2 years or older with advanced cancer enrolled onto the Pediatric Quality of L

156 uited to the PEACE (Posthumous Evaluation of Advanced Cancer Environment) post-mortem study.

157 the oropharynx or gastrointestinal tract or advanced cancer, evaluate for associated symptoms, treat

158 hat immune effector cells from patients with advanced cancers exhibit reduced activation of IFN signa

159 Conclusion Individuals with advanced cancer experience a heavy burden of hospitaliza

160 Children with advanced cancer experience high symptom distress.

161 Purpose Patients with advanced cancer experience potentially burdensome transi

162 pessimism about the ability of drugs to cure advanced cancers, facilitated the study of adjuvant chem

163 with radiation therapy for men with locally advanced cancers (for whom a survival benefit was establ

164 Purpose Among individuals with advanced cancer, frequent hospitalization increasingly i

165 Patients with advanced cancer frequently experience anorexia and cache

166 Most patients with advanced cancer had never received any form of spiritual

167 Medicare patients with advanced cancer have low rates of hospice use.

168 mmonly in neoplasia but its contributions to advanced cancer have not been assessed directly.

169 a occurs early on in tumor development, many advanced cancers have coopted the tissue repair function

170 These challenges demonstrate the need for advanced cancer imaging informatics tools that can help

171 nt-initiated palliative care consultation in advanced cancer improves quality of life in patients wit

172 ) to providers and families of children with advanced cancer improves symptom distress and health-rel

173 r 2003 through May 2008 of 322 patients with advanced cancer in a rural, National Cancer Institute-de

174 ytes (TIL) results in complete regression of advanced cancer in some patients, but the efficacy of th

175 ppropriate palliative care for patients with advanced cancer in sub-Saharan Africa.

176 of rehospitalization among individuals with advanced cancer in the year after diagnosis.

177 ace many challenges caring for patients with advanced cancer: inadequate funding; inequitable distrib

178 ed promise in the treatment of patients with advanced cancers including glioblastoma, the factors dic

179 n is a poor prognosis marker in a variety of advanced cancers, including colorectal, breast, and lung

180 s of 12 to 41% at 24 weeks) in patients with advanced cancers, including non-small-cell lung cancer,

181 botic tendency will persist in patients with advanced cancer, indefinite treatment is generally recom

182 Positive religious coping in patients with advanced cancer is associated with receipt of intensive

183 Although the prognosis for patients with advanced cancer is poor--a five-year survival of only 30

184 Advanced cancer is reduced with screening for women aged

185 Parenting a child with advanced cancer is strongly associated with high to seve

186 The generalizability to all patients with advanced cancer is uncertain.

187 r skeletal muscle anabolism in patients with advanced cancer is unproven.

188 oss of epithelial integrity is a hallmark of advanced cancer, it remains poorly understood whether ge

189 the repertoire of targetable alterations in advanced cancers, it is necessary to sequence recurrent

190 it also seems to act as a tumor promoter in advanced cancer leading to metastasis.

191 astases and vasogenic edema in patients with advanced cancer, leading to reduced morbidity and associ

192 sk factors include higher age, previous VTE, advanced cancer, length of operation and immobility.

193 Children with advanced cancer may not be receiving key elements of pal

194 Among this cohort of 590 patients with advanced cancer (median survival, 5.4 months), 71% wante

195 delaying first on-study SRE in patients with advanced cancer metastatic to bone or myeloma.

196 Patients with advanced cancer (N = 253) were randomly assigned to manu

197 ncer treatment in special populations (e.g., advanced cancer, non-western populations), or on broad d

198 In fatigued patients with advanced cancer, nurse-led monitoring and protocolized t

199 erapy (odds ratio, 1.74; 95% CI, 1.48-2.03), advanced cancer (odds ratio, 2.57; 95% CI, 1.44-4.60), a

200 ory approval in any country for treatment of advanced cancer of that type.

201 decreased across many tumor types, including advanced cancers of the breast and prostate.

202 Importance: Patients with advanced cancer often report expectations for survival t

203 sed on a variety of epithelial cancers, with advanced cancers often expressing FR at significantly hi

204 Most patients with advanced cancer, oncologists, and oncology nurses value

205 between 51 oncologists and 270 patients with advanced cancer; oncologists also completed surveys.

206 Patients with locally advanced cancer or distant metastasis frequently receive

207 family of a hospitalized patient dying with advanced cancer or hematologic disease in which the limi

208 utility indices and was least recommended in advanced cancer or palliative care.

209 per week, children age >/= 2 years old with advanced cancer or their parent completed the computer-b

210 In cachectic patients with advanced cancer, oral melatonin 20 mg at night did not i

211 estigation examining factors associated with advanced cancer patient and caregiver well-being.

212 We performed a dose-escalation study in advanced cancer patients administering oral everolimus 5

213 velopment process, little is known about how advanced cancer patients enrolled onto early phase clini

214 We interviewed 102 advanced cancer patients enrolled onto phase I clinical

215 Advanced cancer patients enrolling onto phase I trials w

216 lopment of the 1F5 mAb, for which studies in advanced cancer patients have been initiated under the n

217 mined religiousness and spiritual support in advanced cancer patients of diverse racial/ethnic backgr

218 We determined the HLA-I genotype of 1535 advanced cancer patients treated with immune checkpoint

219 Many advanced cancer patients' spiritual needs are not suppor

220 e end-of-life (EOL) care for black and white advanced cancer patients.

221 tumor regressions in approximately 10-20% of advanced cancer patients.

222 rmaceuticals Special Scheme was evaluated in advanced cancer patients.

223 Advanced-cancer patients (n = 368; median survival: 196

224 nti-CTLA-4 blocking monoclonal antibodies to advanced-cancer patients increases immune-mediated tumor

225 ll adhesion marker, CD44, is associated with advanced cancer phenotypes.

226 whether in the type of resection in locally advanced cancer plays a role in prognosis and whether TH

227 , few data for specific interventions in the advanced cancer population are available, and thus more

228 linical trials of targeted therapies against advanced cancers published from 1985 to 2005.

229 tilization, and survival in ED patients with advanced cancer randomized to ED-initiated palliative ca

230 The observed differences in advanced cancer rates between African American and white

231 The authors evaluated whether overall and advanced cancer rates were similar across racial and eth

232 All eligible patients with advanced cancer receiving palliative radiation therapy a

233 The median survival of 212 patients with advanced cancer referred to phase I care after the initi

234 Patients (N = 178) with advanced cancers refractory to prior chemotherapy whom o

235 Fifty percent of adults with advanced cancer, regardless of age, will experience a fa

236 A lack of effective treatments for advanced cancer remains a major challenge in oncology.

237 tack mtDNA and exhibited otherwise-resistant advanced cancer sensitive to cisplatin-based chemotherap

238 Clinicians working with patients who have advanced cancer should consider IMCP as an approach to e

239 ommendations Inpatients and outpatients with advanced cancer should receive dedicated palliative care

240 Supportive care programs for patients with advanced cancer should reconsider the services that they

241 The sample included patients with advanced cancer (solid tumors); those with neurologic di

242 In multivariate analyses, advanced cancer stage and outpatient treatment alone wer

243 at high levels of MDSCs correlated with more advanced cancer stage and with reduced survival (p = 0.0

244 Health care access and advanced cancer stage are associated with oncologic outc

245 CD patients were diagnosed at a more advanced cancer stage than UC.

246 prognostic ability in patients with early to advanced cancer stage.

247 CD patients present with a more advanced cancer stage.

248 associated with high histological grade and advanced cancer stage.

249 This expression significantly increases at advanced cancer stages, providing an improved opportunit

250 nts with agitated delirium in the setting of advanced cancer, the addition of lorazepam to haloperido

251 In advanced cancers, the TGF-beta pathway acts as an oncoge

252 nd supportive care options for patients with advanced cancer throughout the continuum of care.

253 friend caregivers of patients with early or advanced cancer to palliative care services.

254 cer are more likely than black patients with advanced cancer to receive the EOL care they initially p

255 Integrins play a role in the resistance of advanced cancers to radiotherapy and chemotherapy.

256 These results also show that the extent of advanced cancer traits, such as invasion, may be determi

257 In this referral population with selected advanced cancers, universal sequencing of a broad panel

258 lliative care consultation for patients with advanced cancer vs usual care took place from June 2011

259 An international biobank of patients with advanced cancer was analyzed.

260 ms, there is support for the hypothesis that advanced cancer was associated with an acute inflammator

261 tion training and coaching for patients with advanced cancer was effective in improving patient-cente

262 In adults with advanced cancer, we aimed to prospectively document the

263 ist intervention to improve communication in advanced cancer, we conducted a post hoc analysis of the

264 rent burden of polypharmacy in patients with advanced cancer, we expect that greater attention to pol

265 prospective clinical sequencing program for advanced cancers, we enrolled 11 patients with ER-positi

266 -five young adults (age 20 to 40 years) with advanced cancer were administered measures of alliance,

267 re rarely investigated because patients with advanced cancer were considered terminal.

268 high-grade dysplasia and submucosal or more advanced cancer were excluded.

269 ear after diagnosis, 71% of individuals with advanced cancer were hospitalized, 16% had three or more

270 In all, 152 fatigued patients with advanced cancer were randomly assigned to protocolized p

271 er 2010 and March 2013, CGs of patients with advanced cancer were randomly assigned to receive three

272 CGs of patients with advanced cancer were recruited from a National Cancer In

273 Since May 2015, 1040 of these patients with advanced cancer were referred by their oncologists for g

274 reatment effectiveness, and offer opioids in advanced cancer when other treatments are unsuccessful.

275 ws the evidence for improved patient care in advanced cancer when patients' individual goals and pref

276 ways to broaden the combinatorial attack on advanced cancers, where immune escape mechanisms likely

277 aintain or even improve QOL in patients with advanced cancer who are undergoing cancer treatment.

278 ted a prospective study of 932 patients with advanced cancer who experienced an unplanned hospitaliza

279 Patients with advanced cancer who report recent discussions of prognos

280 study assessed outcomes of individuals with advanced cancer who required admission to an intensive c

281 erience with 2,000 consecutive patients with advanced cancer who underwent testing on a genomic testi

282 Participants with advanced cancer who viewed a video of CPR were less like

283 inal cohort study of 265 adult patients with advanced cancer who visited 38 oncologists within commun

284 Adult patients with advanced cancer who were able to pass a cognitive screen

285 cluding English-speaking adult patients with advanced cancer who were able to understand the nature o

286 Conclusion Patients with advanced cancer who were discharged to PAC facilities an

287 380 adults with advanced cancer who were experiencing moderate-to-severe

288 gn, Setting, and Participants: Patients with advanced cancer who were referred to dermatology at Yale

289 ve, longitudinal cohort of 345 patients with advanced cancer, who were enrolled between January 1, 20

290 Patients with advanced cancer with >/= three CRF-related symptoms (ie,

291 Patients with advanced cancer with a fatigue score of >/= 4 out of 10

292 ism, smoking cessation, and in patients with advanced cancer with anxiety.

293 e at the time of diagnosis and treatment for advanced cancer with life-limiting prognosis.

294 cient germline cells and in various types of advanced cancers with a poor prognosis.

295 itor SCCA1 (SERPINB3) is upregulated in many advanced cancers with poor prognosis, but there is limit

296 a phase I/II clinical trial in patients with advanced cancers without harming normal cells or tissues

297 in a phase I clinical trial in patients with advanced cancers without harming normal cells.

298 of life (QOL), and aggressive treatments in advanced cancer, yet few randomized clinical trials (RCT

299 l adhesion kinase (FAK) expression occurs in advanced cancers, yet a signaling role for FAK in tumor

300 Thousands of children are living with advanced cancer; yet patient-reported outcomes (PROs) ha